## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%); PEG 14.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($23.83)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance**
- Source: BioSpace | 20251217T113137 | Somewhat-Bullish | Relevance: 100%
- Pfizer (NYSE:PFE) has reaffirmed its full-year 2025 Adjusted Diluted EPS guidance and adjusted its 2025 revenue guidance to approximately $62.0 billion. The company also announced its full-year 2026 guidance, projecting revenues between $59.5 to $62.5 billion and Adjusted Diluted EPS in the range of $2.80 to $3.00, reflecting continued strategic investments in its pipeline and acquired assets despite anticipated declines from COVID-19 product sales and loss of exclusivity for certain products.

**2. Pfizer's Oncology and Obesity Pipelines Support a Narrow Moat Despite Looming Patent Expirations**
- Source: Morningstar | 20251217T050844 | Somewhat-Bullish | Relevance: 100%
- Pfizer's strong oncology and obesity drug pipelines are expected to help the company maintain a narrow economic moat, despite facing upcoming patent expirations. The company's large scale and diversified portfolio of patent-protected drugs continue to underpin its business strategy. Recent divestments of its off-patent and consumer businesses aim to refocus Pfizer on its innovative drug development.

**3. Shorepoint Capital Partners LLC Invests $3.06 Million in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251216T120904 | Somewhat-Bullish | Relevance: 100%
- Shorepoint Capital Partners LLC has initiated a new position in Pfizer Inc. (NYSE:PFE), acquiring 120,211 shares valued at approximately $3.06 million in the third quarter. Other institutional investors like Vanguard, Geode Capital Management, Norges Bank, Northern Trust Corp, and Amundi also significantly adjusted their holdings, bringing total institutional ownership to about 68.36%. Pfizer, with a market cap of around $150.4 billion, recently announced a quarterly dividend of $0.43 per share, yielding approximately 6.5%.

**4. Thrivent Financial for Lutherans Increases Stake in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251217T103332 | Neutral | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its holdings in Pfizer Inc. (NYSE:PFE) by 16.0% in the second quarter, bringing its total stake to 605,236 shares valued at $14.67 million. Several other institutional investors also adjusted their positions in Pfizer, with notable increases from Bourne Lent Asset Management Inc., Ossiam, and IFM Investors Pty Ltd. Pfizer's stock opened at $25.56, and the company recently announced a quarterly dividend of $0.43 per share, representing an annualized yield of 6.7%.

**5. Pfizer reaffirms 2025 earnings guidance (PFE:NYSE)**
- Source: Seeking Alpha | 20251216T121348 | Neutral | Relevance: 100%
- Pfizer Inc. reaffirmed its 2025 adjusted earnings per share outlook but revised its revenue forecast for the year to be slightly below Street expectations. This announcement was made ahead of a conference call with investment analysts. The company's stock symbol is PFE.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $27 | $28 | -4% |
| 2025-12-15 | B of A Securiti | $28 | $29 | -3% |
| 2025-12-12 | Morgan Stanley | $28 | $32 | -12% |
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | main | Equal-Weight |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.2% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 14.2x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 14.22 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment negative (3 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.4B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 14.22 |
| Forward P/E | 8.3 |
| Current P/E | 8.0 |
| YoY Growth | -3.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.1% to -1.1% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). RSI neutral at 46. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.14% (CS: 26) | Neutral |
| RSI_14 | 45.8 | Neutral |
| MACD Histogram | -0.08 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 1.021x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.05
- **Stop Loss:** $23.83 (4.9% risk)
- **Target:** $26.27 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 778
- **Position Value:** $19,488.90
- **Portfolio %:** 19.49%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*